カテゴリ： GlobalData, アメリカ, 企業調査

Melinta Therapeutics Inc (MLNT)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Melinta Therapeutics Inc (MLNT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C11496
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：98
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Melinta Therapeutics Inc (Melinta) is a biopharmaceutical company that focuses on the development of novel antibiotics. Its drugs are intended to treat the various bacterial infections. The company’s lead product Baxdela (delafloxacin) has been approved by the US FDA as an IV treatment for serious skin infections known as acute bacterial skin and skin structure infections (ABSSSI). Delafloxacin is also being as an investigational antibiotic for Serious Community-Acquired Bacterial Pneumonia (CABP) and Complicated Urinary Tract Infections (cUTI). It also has multiple Oxazolidinone and Macrolide Programs in Pre-clinical and Clinical studies. The products are based on its ribosome crystallography platform, engineered to overcome the problem of drug resistance. The company has partnerships with Menarini Group; Malin Plc; Eurofarma Laboratorios for the commercialization of its products. Melinta is headquartered at New Haven, Connecticut, the US.

Melinta Therapeutics Inc (MLNT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 12
Venture Financing 14
Melinta Therapeutics Raises USD67 Million in Series 4 Venture Financing 14
Melinta Therapeutics Secures Additional USD10 Million from Hercules Technology Growth Capital 15
Melinta Therapeutics Raises US$70 Million In Series 3 Financing 16
Rib-X Pharma Raises US$19 Million In First Tranche Of Series 2 Financing 17
Private Equity 19
Melinta Therapeutics to Raise Funds through Financing Round 19
Partnerships 20
Melinta Therapeutics Enters into Agreement with Menarini 20
Melinta Therapeutics Expands Agreement with Eurofarma Lab 21
Cempra Pharma Enters into Agreement with BARDA 22
Merger 23
Melinta Therapeutics and Cempra Merge 23
Licensing Agreements 25
Menarini Enters into Licensing Agreement with Melinta Therapeutics 25
Cempra Pharma Enters into Option and Licensing Agreement with Macrolide Pharma 26
Equity Offering 27
Melinta Therapeutics Raises USD123.2 Million in Public Offering of Shares 27
Melinta Therapeutics Plans to Raise USD115 Million in Public Offering of Shares 29
Rib-X Pharma Withdraws IPO 30
Acquisition 31
Medicines Company Acquires Rempex Pharma For US$474 Million 31
Melinta Therapeutics Inc – Key Competitors 33
Melinta Therapeutics Inc – Key Employees 34
Melinta Therapeutics Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 07, 2018: Melinta Therapeutics reports third quarter 2018 financial results 36
Aug 07, 2018: Melinta Therapeutics Reports Second Quarter 2018 Financial Results 38
May 08, 2018: Melinta Therapeutics Reports First Quarter 2018 Financial Results 40
Mar 13, 2018: Melinta Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 42
Corporate Communications 44
Oct 31, 2018: Melinta Therapeutics announces appointment of Bruce L. Downey to Board of Directors 44
Oct 22, 2018: Melinta Therapeutics appoints John H. Johnson as Interim Chief Executive Officer 45
Sep 18, 2018: Melinta Therapeutics appoints Peter Milligan as Chief Financial Officer 46
Oct 31, 2017: Melinta and Cempra Name Industry Leader Daniel Wechsler as President and Chief Executive Officer of the Combined Company 47
Oct 31, 2017: Melinta and Cempra Announce Accomplished Executive Leadership Team for Combined Organization 48
Product News 51
10/30/2017: Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States 51
09/28/2017: The Medicines Company to Present Data On ORBACTIV (oritavancin) At IDWeek 2017 52
09/22/2017: Melinta Therapeutics to Participate in Two Upcoming Investor Conferences 53
08/30/2017: The Medicines Company Announces FDA Approval of VABOMERE (meropenem and vaborbactam) 54
08/29/2017: FDA approves new antibacterial drug 56
06/19/2017: Melinta Therapeutics Announces U.S. FDA Approval of Baxdela (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections 57
05/31/2018: Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20 Presentations at ASM Microbe 2018 58
05/30/2017: The Medicines Company to Present Data on Orbactiv at ASM Microbe 2017 59
04/23/2018: Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018 61
04/17/2017: The Medicines Company to Present Data on Orbactiv (oritavancin) at ECCMID 2017 62
04/16/2018: Melinta Therapeutics to Present New Findings from Pyrrolocytosine Candidate RX-P2382 at ECCMID 2018 64
01/29/2018: Melinta Therapeutics Launches Antibiotic Baxdela (delafloxacin) in the United States 65
Product Approvals 66
Mar 08, 2018: Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe 66
Feb 20, 2018: Melinta Therapeutics’ Commercial Partner Eurofarma Laboratories Submits Marketing Authorization Application for Delafloxacin in Argentina 67
Aug 02, 2017: Firma Provides Support Associated with FDA Approval of Melinta Therapeutics’ Baxdela (delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 68
Feb 21, 2017: The Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic Carbavance (meropenem-vaborbactam) 69
Clinical Trials 70
Nov 13, 2017: Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne 70
Oct 24, 2017: Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities 71
Oct 10, 2017: Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne 72
Oct 05, 2017: The Medicines Company to Present New Data from TANGO II Study of VABOMERE™ (meropenem and vaborbactam) at IDWeek 2017 73
Oct 04, 2017: Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek 76
Sep 28, 2017: The Medicines Company to Present Data On VABOMERE (meropenem and vaborbactam) at IDWeek 2017 78
Sep 25, 2017: Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections 82
Sep 18, 2017: Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens 84
Jul 25, 2017: The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE 85
May 30, 2017: The Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including Late-Stage Investigational Antibiotic Meropenem-Vaborbactam 87
Apr 17, 2017: The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam 91
Feb 24, 2017: Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI 94
Other Significant Developments 96
May 11, 2018: Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance 96
Nov 03, 2017: Cempra Announces Preliminary Results of 2017 Stockholder Vote 97
Appendix 98
Methodology 98
About GlobalData 98
Contact Us 98
Disclaimer 98

List of Tables
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Melinta Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 12
Melinta Therapeutics Raises USD67 Million in Series 4 Venture Financing 14
Melinta Therapeutics Secures Additional USD10 Million from Hercules Technology Growth Capital 15
Melinta Therapeutics Raises US$70 Million In Series 3 Financing 16
Rib-X Pharma Raises US$19 Million In First Tranche Of Series 2 Financing 17
Melinta Therapeutics to Raise Funds through Financing Round 19
Melinta Therapeutics Enters into Agreement with Menarini 20
Melinta Therapeutics Expands Agreement with Eurofarma Lab 21
Cempra Pharma Enters into Agreement with BARDA 22
Melinta Therapeutics and Cempra Merge 23
Menarini Enters into Licensing Agreement with Melinta Therapeutics 25
Cempra Pharma Enters into Option and Licensing Agreement with Macrolide Pharma 26
Melinta Therapeutics Raises USD123.2 Million in Public Offering of Shares 27
Melinta Therapeutics Plans to Raise USD115 Million in Public Offering of Shares 29
Rib-X Pharma Withdraws IPO 30
Medicines Company Acquires Rempex Pharma For US$474 Million 31
Melinta Therapeutics Inc, Key Competitors 33
Melinta Therapeutics Inc, Key Employees 34
Melinta Therapeutics Inc, Subsidiaries 35

List of Figures
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Melinta Therapeutics Inc (MLNT)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Banco Pan S.A. (BPAN4)：企業の財務・戦略的SWOT分析
    Banco Pan S.A. (BPAN4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Dynavax Technologies Corp (DVAX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Dynavax Technologies Corp (Dynavax), formerly Double Helix Corp, is a clinical-stage biopharmaceutical company that develops product candidates for the prevention of infectious and inflammatory disease. The company’s only marketed product Heplisav-B is an adult vaccine for hepatitis B. Its p …
  • Eftec AG：企業の戦略的SWOT分析
    Eftec AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Cabot Energy Plc (CAB)：石油・ガス：M&Aディール及び事業提携情報
    Summary Cabot Energy Plc (Cabot), formerly Northern Petroleum, is an independent upstream oil and gas company. It explores for, develops, and produces oil and natural gas; and trades assets. The company operates in onshore and offshore projects including gas producing fields and oil fields. Cabot's …
  • CardioFocus Inc-医療機器分野：企業M&A・提携分析
    Summary CardioFocus Inc (CardioFocus) is a medical device company that manufactures and distributes investigating disposable fiber optic catheters and endoscopic products. The company provides cardiofocus endoscopic ablation system that consists of balloon catheter, deflectable sheath introducer, en …
  • Nanyang Technological University：企業の戦略的SWOT分析
    Nanyang Technological University - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Interconexion Electrica SA ESP (ISA)：企業の財務・戦略的SWOT分析
    Interconexion Electrica SA ESP (ISA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Toa Corp (1885)：企業の財務・戦略的SWOT分析
    Toa Corp (1885) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Varex Imaging Corp (VREX)：企業の財務・戦略的SWOT分析
    Varex Imaging Corp (VREX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Metropolitan Bank and Trust Company：企業の戦略・SWOT・財務分析
    Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report Summary Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Genomic Health Inc (GHDX)-医療機器分野：企業M&A・提携分析
    Summary Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company’s commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer …
  • Sound Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Sound Pharmaceuticals Inc (SPI) is a biopharmaceutical company that develops therapeutics for sensorineural otologic diseases. The company's product pipeline includes SPI-1005, SPI-3005 and SPI-5557. Its SPI-1005 is a proprietary oral formulation of ebselen, a small molecule mimic and induce …
  • HC2 Holdings, Inc.：企業のM&A・事業提携・投資動向
    HC2 Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HC2 Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • AMO Pharma Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary AMO Pharma Ltd (Amo Pharma) is a biopharmaceutical company that develops novel treatments for serious and debilitating diseases. The company provides pipeline product portfolio such as AMO-01, and AMO-02. Its AMO-01 is being developed for the treatment of autism and intellectual disabilities …
  • Chenguang Biotech Group Co Ltd (300138)：企業の財務・戦略的SWOT分析
    Chenguang Biotech Group Co Ltd (300138) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • ROSEN Swiss AG：企業の戦略的SWOT分析
    ROSEN Swiss AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • SOCO International Plc (SIA)：石油・ガス：M&Aディール及び事業提携情報
    Summary SOCO International Plc (SOCO) is an oil and gas company that explores, discovers and produces oil and gas reserves. The company offers appraisal and field development services. It provides training and skills and support local communities. SOCO produces and supplies natural resources. SOCO h …
  • General Re Corporation：企業の戦略的SWOT分析
    General Re Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Maines Paper & Foodservice, Inc.：企業の戦略・SWOT・財務情報
    Maines Paper & Foodservice, Inc. - Strategy, SWOT and Corporate Finance Report Summary Maines Paper & Foodservice, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Belfius Bank Sa：企業の戦略・SWOT・財務分析
    Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report Summary Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆